Draxler Dominik F, Johannes Judith Karen, Nakase Masaaki, Heg Dik, Dobner Stephan, Turovskij Elisabeth, Fürholz Monika, Häner Jonas, Lanz Jonas, Pilgrim Thomas, Hunziker Lukas, Praz Fabien, Räber Lorenz, Rohla Miklos, Siontis George C M, Susuri-Pfammatter Njomeza, Windecker Stephan, Stortecky Stefan
Department of Cardiology Inselspital, Bern University Hospital, University of Bern Switzerland.
Department of Clinical Research University of Bern Switzerland.
J Am Heart Assoc. 2025 May 6;14(9):e035916. doi: 10.1161/JAHA.124.035916. Epub 2025 Apr 25.
Ultrasound-assisted catheter-directed thrombolysis (USAT) for acute pulmonary embolism (PE) has garnered specific interest and is commonly employed in intermediate-risk PE to prevent cardiac decompensation and death. However, evidence supporting the effectiveness and safety of USAT in routine clinical practice is limited. We therefore aimed to investigate the safety and effectiveness of USAT in a large patient population with PE.
The ERASE PE (Bern Acute Pulmonary Embolism Registry) is a single-center cohort study investigating the safety and effectiveness of PE treatment according to the decision of the local PE response team. The specified primary outcome was in-hospital mortality. Between October 2017 and April 2023, 315 patients (mean age 64.3±14.2 years; 38% female) with intermediate-high (n=257, 82%) and high risk (n=58, 18%) PE were treated with USAT. Patients presented with tachycardia (heart rate 104.3±20.4 bpm), hypoxemia (peripheral oxygen saturation 89.2%±7.5%), elevated mean pulmonary artery pressures (30.7±8.0 mm Hg), and reduced mixed venous saturation (venous oxygen saturation 58.5%±10.2%). Patients received USAT with a cumulative dose of 19.8±6.6mg rt-PA over 14.4±2.2 hours. USAT was effective in reducing right ventricular overload and pulmonary artery pressure in 88% of patients with a mean reduction of right ventricular/left ventricular ratio of 0.37±0.29 and mean pulmonary artery pressure of 8.5±7.7 mm Hg, respectively. The primary end point was observed in 10 patients (3.2%). One patient had an embolic stroke (0.3%), 25 patients (7.9%) exhibited bleeding, including 3 patients with intracranial hemorrhage (1.0%), and 3 patients (1.0%) had recurrent PE.
Among patients with acute PE, USAT effectively reduces right ventricular overload and mean pulmonary artery pressure with low rates of in-hospital mortality and bleeding.
URL: https://www.clinicaltrials.gov; Unique identifier: NCT04355975.
超声辅助导管定向溶栓术(USAT)治疗急性肺栓塞(PE)已引起特别关注,常用于中危PE以预防心脏失代偿和死亡。然而,支持USAT在常规临床实践中有效性和安全性的证据有限。因此,我们旨在研究USAT在大量PE患者中的安全性和有效性。
ERASE PE(伯尔尼急性肺栓塞登记研究)是一项单中心队列研究,根据当地PE反应团队的决策调查PE治疗的安全性和有效性。指定的主要结局是住院死亡率。2017年10月至2023年4月期间,315例中高危(n = 257,82%)和高危(n = 58,18%)PE患者接受了USAT治疗(平均年龄64.3±14.2岁;38%为女性)。患者表现为心动过速(心率104.3±20.4次/分)、低氧血症(外周血氧饱和度89.2%±7.5%)、平均肺动脉压升高(30.7±8.0 mmHg)和混合静脉血氧饱和度降低(静脉血氧饱和度58.5%±10.2%)。患者接受USAT治疗,在14.4±2.2小时内rt-PA累积剂量为19.8±6.6mg。USAT在88%的患者中有效降低了右心室负荷和肺动脉压,右心室/左心室比值平均降低0.37±0.29,平均肺动脉压降低8.5±7.7 mmHg。10例患者(3.2%)观察到主要终点。1例患者发生栓塞性卒中(0.3%),25例患者(7.9%)出现出血,包括3例颅内出血患者(1.0%),3例患者(1.0%)发生复发性PE。
在急性PE患者中,USAT能有效降低右心室负荷和平均肺动脉压,住院死亡率和出血发生率较低。